A Phase IIa, Open-label, Multiple Ascending Dose Confirmation Study of the Safety and Tolerability of Intravenous Brincidofovir in Subjects with Adenovirus Infection

Administered By

Awarded By

Contributors

Start/End

  • February 23, 2022 - December 1, 2025